5-MeO-AET

5-MeO-AET
Clinical data
Other names5-Methoxy-α-ethyltryptamine; 5-MeO-αET; 5-MeO-AET
Routes of
administration		Oral[1]
Drug classSerotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Identifiers
  • 1-(5-methoxy-1H-indol-3-yl)butan-2-amine
CAS Number
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H18N2O
Molar mass218.300 g·mol−1
3D model (JSmol)
Melting point201 to 203 °C (394 to 397 °F)
  • CCC(N)Cc2c[nH]c1ccc(cc12)OC
  • InChI=1S/C13H18N2O/c1-3-10(14)6-9-8-15-13-5-4-11(16-2)7-12(9)13/h4-5,7-8,10,15H,3,6,14H2,1-2H3 Y
  • Key:JHTPCKWBFLMJMQ-UHFFFAOYSA-N Y
  (verify)

5-Methoxy-α-ethyltryptamine (5-MeO-αET) is a psychoactive drug and member of the tryptamine family.[1] It reportedly produces psychedelic and stimulant effects.[1][2]

Use and dosage

5-MeO-αET, when used recreationally, is usually taken orally at doses of 50 to 75 mg.[1]

Effects

5-MeO-αET produces entactogenic and stimulant effects that can last 4 to 6 hours. However, little information exists on the psychopharmacological effects of this compound, thus considerable variation with regard to dosage and effects can be expected.

Dangers

There have been no reported deaths or hospitalizations from 5-MeO-αET, but its safety profile is unknown.

Pharmacology

The pharmacology of 5-MeO-αET has been studied.[3] It is a weak partial agonist of the serotonin 5-HT2A receptor, with a binding affinity (Ki) of 4,073 nM, an EC50Tooltip half-maximal effective concentration of 166 nM, and an EmaxTooltip maximal efficacy of 34%.[3] For comparison, αET showed 14-fold lower affinity for the receptor than 5-MeO-αET and was inactive as an agonist of the receptor.[3] The individual stereoisomers of 5-MeO-αET and αET were also assessed.[3]

5-MeO-αET is unscheduled and uncontrolled in the United States, but possession and sales of 5-MeO-αET could be prosecuted under the Federal Analog Act because of its structural similarities to αET and αMT.

See also

References

  1. ^ a b c d Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Retrieved 1 February 2025.
  2. ^ Deluca P, Davey Z, Corazza O, Di Furia L, Farre M, Flesland LH, et al. (December 2012). "Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 39 (2). Elsevier BV: 221–226. doi:10.1016/j.pnpbp.2012.07.011. PMID 22841965. S2CID 22296279.
  3. ^ a b c d Jones, Charles (2024). Exploration of Dopaminergic and Serotonergic Pathways Utilizing Pleiotropic Agents (Thesis). VCU Libraries. doi:10.25772/8c2h-h502. Retrieved 18 May 2025.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.